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Abstract
Hepatitis C virus (HCV) is a highly mutable RNA virus and circulates as a heterogeneous population in individual patients.
The magnitude of such population heterogeneity has long been proposed to be linked with diverse clinical phenotypes,
including antiviral therapy. Yet data accumulated thus far are fairly inconclusive. By the integration of long RT-PCR with 454
sequencing, we have built a pipeline optimized for the quantification of HCV genome-wide mutation load at 1% resolution
of mutation frequency, followed by a retrospective study to examine the role of HCV mutation load in peginterferonalpha2a and ribavirin combination antiviral therapy. Genome-wide HCV mutation load varied widely with a range from 92 to
1639 mutations and presented a Poisson distribution among 56 patients (Kolmogorov-Smirnov statistic = 0.078, p = 0.25).
Patients achieving sustained virological response (n = 26) had significantly lower mutation loads than that in null responders
(n = 30) (mean and standard derivation: 5246279 vs. 8056271, p = 0.00035). All 36,818 mutations detected in 56 patients
displayed a power-law distribution in terms of mutation frequency in viral population. The low-frequency mutation load,
but not the high-frequency load, was proportional firmly to the total mutation load. In-depth analyses revealed that intrapatient HCV population structure was shaped by multiple factors, including immune pressure, strain difference and genetic
drift. These findings explain previous conflicting reports using low-resolution methods and highlight a dominant role of
natural selection in response to therapeutic intervention. By attaining its signatures from complex interaction between host
and virus, the high-resolution quantification of HCV mutation load predicts outcomes from interferon-based antiviral
therapy and could also be a potential biomarker in other clinical settings.
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potential links with disease traits in various clinical settings,
including disease progression and responses to antiviral therapy.
However, data accumulated thus far appear to be conflicting [3].
With the introduction of next-generation sequencing, it is rapidly
appreciated that a large body of viral mutations, due to their low
frequency, may be beyond the detection of common methods,
including cloning and Sanger sequencing [4]. In the current study,
we have first built a technical platform for genome-wide
quantification of HCV mutation load at a one percentage
resolution of mutation frequency in viral population. Using patient
samples from the well-characterized the Hepatitis C Antiviral
Long-term Treatment against Cirrhosis (HALT-C) Trial [5], a
retrospective study was then conducted to explore the role of viral

Introduction
As a result of error-prone replication and high turnover rate,
RNA viruses in persistent infection circulate as a heterogeneous
population, sometimes referred as viral quasispecies [1]. The
structure of such heterogeneous populations, as shaped theoretically by interactions between host and viruses, may reflect intrinsic
pathophysiological status of underlying diseases and may act as a
virulence factor to affect disease progression [2]. Given the broad
clinical spectrum of resulting diseases as seen with human
immunodeficiency virus (HIV) and hepatitis C virus (HCV),
heterogeneous viral population structure, measured either by
diversity or diversification, has been studied extensively for
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Figure 2. Neighbor-joining tree of HCV HVR1 variants recovered by either 454 sequencing (red) or cloning/Sanger
sequencing (black) in five patient samples. The tree was
constructed under maximum composition likelihood model with
bootstrap support (percentage) shown on major branches.
doi:10.1371/journal.pone.0100131.g002

The remaining 60 serum samples were requested from HALTC trial [5]. Samples were collected from patients prior to 48-week
full-dose combination peginterferon/ribavirin antiviral therapy
[5]. Among them 30 patients achieved sustained virological
response (SVR) and the other had null response as determined
in the parent study. To minimize the role of demographic and
other factors in final data interpretation, these patients were well
matched in terms of sex (all male), ethnic background (all
Caucasian), age, body mass index (BMI) liver fibrosis and
necroinflammation estimated by Ishak scoring system [7] (Table
S1). All patients had HCV genotype 1a infection, as determined by
line probe assay (Innogenetics, Belgium) in the parent study. Upon
receiving samples, genotype was further confirmed by phylogenetic analysis of a HCV NS5b region through direct amplicon
sequencing. HCV RNA titers in all patients were measured using
Roche Amplicor HCV Monitor (version 2.0). Of sixty patients, 54
had IL28B genotype data available from the parent study (Table
S1).

Figure 1. Simulation of the sequencing depth required for
stable quantitation of HCV mutation load at a resolution of 1%
mutation frequency in population. Five patient samples with
known intra-population genetic diversity were subject to 454 sequencing. Starting at an average base coverage of 1100x, the genome-wide
HCV mutation load became stable with overall 98% saturation (A) and
had a weak correlation with genetic diversity measured by cloning and
sanger sequencing (R2 = 0.18, p = 0.26) (B).
doi:10.1371/journal.pone.0100131.g001

population structures in HCV antiviral therapy together with
evolutionary and clinical interpretations.

Materials and Methods
Patient samples
Sixty-five serum samples from patients with chronic HCV 1a
infection were used in the current study. Of them four serum
samples were from a completed study that investigated the role of
intra-patient HCV population diversity through Sanger sequencing of 15 clones derived from partial HCV envelope region, which
spanned the HCV hypervariable region 1 (HVR1) (for simplicity,
named HVR1 diversity) [6]. These samples were selected based on
their HVR1 diversity, representing high, moderate and low points
on its exponential distribution curve [6]. Serum sample H77, the
prototype of HCV 1a in the USA, was kindly provided by Dr.
Robert Purcell (NIH). The HVR1 diversity of H77 was measured
using the same method as described previously [6]. These five
samples were used to estimate potential bias associated with the
long RT-PCR as well as Roche/454 sequencing depth that
reaches quantitative saturation of mutation load at the resolution
of 1% mutation frequency.
PLOS ONE | www.plosone.org

Ethics Statement
For collection of serum samples, a written informed consent was
obtained from each patient and was approved by local Institutional Review Board in the parental studies [5]. The research
protocol for the use of these patient samples was reviewed and
approved by the Saint Louis University Institutional Review Board
(IRB protocol: SLU15565).

RNA extraction, long RT-PCR and 454 sequencing
Total RNA from each serum sample was extracted from 280 mL
serum and eluted into 60 mL Tris buffer (pH 8.5) using QIAamp
Viral RNA Mini kit (Qiagen, Valencia, CA). Long RT-PCR was
then applied to amplify a 9022-bp amplicon spanning approximately 96% HCV genome using an optimized protocol as we
described previously [8]. In brief, 10.6 mL of extracted RNA was
2
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Figure 3. Linear regression analysis of the correlation among reads supporting each HVR1 structural variant (SV) recovered at
various sequencing depths in samples #1701 (A) and #1709 (B). Data were extracted randomly in a range of sequencing depths starting at
1100x, a saturation point for the mutation load. At the depth of 1100x, samples #1701 and #1709 had 4 and 10 HVR1 structural variants,
respectively, which were not changed up to the depth of 4600x. In each sample, the correlation between HVR1 structural variant 1 (SV1) and the
other variants (SV2 through SV3 in #1701 and SV2 through SV10 in #1709) was highly stable throughout the sequencing depths (all R2.0.95, p,
0.0001).
doi:10.1371/journal.pone.0100131.g003

mixed with 9.4 mL RT matrix consisting of 1x SuperScript III
buffer, 10 mM DTT, 1 mM QR2 (reverse primer), 2 mM dNTPs,
20 U of RNasein Ribonuclease Inhibitor, 200 U of SuperScript
III (Life technologies) and 5 U AMV (Promega). After incubation
at 50uC for 75 min, five microliters of RT reaction was applied for
the first round of PCR that contained 1.25 mM Mg(OAc)2, 1x XL
PCR buffer, 2 mM dNTPs, 0.4 mM Trnc-21, 0.4 mM of each
primer (WF33 and QR2), and 2 U rTth XL DNA polymerase
(Applied Biosystems). Cycle parameters were programmed as
94uC for 1 min followed by the first 10 cycles of 94uC for 30 sec
and 65uC for 9 min and final 20 cycles in which the annealing/
elongation temperature was reduced to 60uC for 9 min with a 3sec autoextension at each cycle. Two microliters of the first round
of PCR product was used for the second round amplification with
primers WF5 and WR55. Cycle parameters were the same as the
first round PCR except for the annealing/elongation temperature
was changed to 72uC in the first 10 cycles and 68uC in the last 20
cycles. Product at expected size was gel-purified using QIAEX II
Gel Extraction Kit (Qiagen). Approximately 3 to 5 mg of purified
product was subjected to the construction of fragment library with
Rapid Library Preparation Kit (Roche Applied Science), followed
by 454 sequencing on GS/FLX Titanium platform.

NS5b. Mapped files were then converted into binary format
(BAM), sorted and indexed in SAMtools [13], followed by local
realignment and base quality recalibration in Genome Analysis
Toolkit (GATK) [14]. The latter used reference SNP (single
nucleotide polymorphism) files that were produced by combined
data from each HCV 1a clade. Base coverage was then computed
with BEDTools [15]. Next, by converting post-alignment BAM
files into mpileup format in SAMtools, the consensus sequence for
each patient sample was called in VarScan (v2.2.3) with the
settings of $100x base coverage, $25 base quality at a position to
count a read and $50% mutation frequency [16]. Entire pipeline
was repeated using individual consensus sequence from each
patient sample. Both mutations and indels (insertions and
deletions) were called at each position in VarScan with the same
settings except for the mutation frequency set at 1%. These indels
were confirmed by manual check using the Integrative Genomics

Sequence data analysis
Raw sequence data in standard flowgram format (sff) were
converted into fasta and qual files using sffinfo command. The
sfffile command was used for random data extraction in simulation
analysis. Raw sequence reads in fastq format, combined from fasta
and qual files, were first filtered in PRINSEQ (v0.19.5) for quality
control, including read length $70 bp, mean read quality score $
25, low complexity with DUST score #7, ambiguous bases #1%
and all duplicates [9]. Filtered reads were mapped onto the
consensus sequences using a gapped aligner Bowtie 2 [10].
Because HCV genotype 1a forms two separate clusters in
phylogenetic trees [8,11], the consensus sequence for each clade
was generated from non-redundant full-length HCV 1a sequences
deposited in Los Alamos HCV database (clade 1 = 271; clade
2 = 124) [12]. The clade attribute of each patient sample was
determined by phylogenetic analysis based on partial domain or
PLOS ONE | www.plosone.org

Figure 4. Average base coverage over 9022-bp amplicon after
read quality control. The amplicon covers 96% HCV genome from
59UTR to NS5b as indicated at the bottom. Grey area represented
standard derivation of the base coverage at each HCV genomic
position.
doi:10.1371/journal.pone.0100131.g004
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Figure 5. Comparative analysis of the mutation load, either average number of mutations per patient (left side) or normalized
entropy (right side), between SVR and null response groups (A). The analysis was done with either synonymous, nonsynonymous or the
combination (A). The histogram of total mutation number, fitting a Poission distribution, gave a more intuitive observation with respect to its
relevance to the outcomes of HCV antiviral therapy (B).
doi:10.1371/journal.pone.0100131.g005

output of Bowtie 2 and patient-specific consensus sequence were
then used as the input of Shorah. Each structural HVR1 variant
recovered from the local analysis came with a posterior probability
and average number of reads supporting the variant. Only
structural variants with posterior probability .90% were considered as an authentic recovery [21].

Viewer (IGV) [17]. Finally, the nature of each mutation, either
synonymous or nonsynonymous, was determined using a custom
script [18].

Distribution pattern analysis
Histograms from either mutation number or frequency were
estimated for distribution patterns (power law, lognormal,
exponential and Poisson) using Clauset’s method [19]. Significance
(p value) of a given pattern evaluated by maximum likelihood
approach was calculated through the goodness-of-fit test based on
the Kolmogorov-Smirnov (KS) statistic and likelihood ratios.
Consequently, null hypothesis is rejected with the p value ,0.1
[19]. The test also provides an estimate of the lower cut-off (xmin)
for the scaling region. All analyses were done with poweRlaw
package in R [20].

Phylogenetic analysis
This analysis was used to explore potential association between
nucleotide sequences (genotype) and disease traits (phenotypes)
through the simulation of phylogenetic topologies [22]. Due to
genome-wide speciation among HCV genotypes, subtypes and
clades, the analysis was performed within each HCV 1a clade
under two phenotypes, i.e., response patterns to antiviral therapy
(SVR vs. null responders) and mutation load (high vs. low). Under
these settings, nearly full-length HCV 1a coding region was
scanned through a sliding window (size = 300 bp, overlap = 99 bp). The analytical pipeline was similar to what we
described previously [23]. In brief, the best-fit nucleotide
substitution model for all HCV domains was determined through
JModelTest [24]. Bayesian Markov chain Monte Carlo (MCMC)
phylogenetic trees were simulated in BEAST package under
selective model (GTR+G) as well as additional parameter settings,
including a relaxed molecular clock, a Bayesian skyline coalescent
prior and a total run of 10 million generations to reach relevant
parameter convergence as estimated by Tracer [25]. The inferred
MCMC trees, after discarding the first 10% trees as burn-in, were
used as the input to estimate the strength of HCV 1a strain
clustering in terms of response pattern or mutation load with 1000
replications in BaTS [22]. Based on empirical and simulated data,
p values of both the association index (AI) and the parsimony score
(PS) less than 0.01 were considered as having statistical significance
[22,24]. Other phylogenetic tree constructions were done with
MEGA program (version 5.2) [26].

Sliding window analysis
The mutation load was measured as the number of mutations or
Shannon Entropy that takes into the account of mutation
frequency [6]. Over the HCV coding region from Core to
NS5b, the mutation load was counted through sliding windows,
size = 300 bp, overlap = 100 bp. Statistical significance at each
window was determined between SVR and null responders.

Recovery of structural HCV HVR1 variants
The HVR1 on the 59 end of HCV E2 is the most variable
region under immune selection and/or viral compartmentation.
For each patient, all structural variants over a 300-bp window
spanning the HVR1 were recovered by the local analysis in
program Shorah [21]. Because 300-bp window size is well below
the average read length (444 bp) in the current study, the local
analysis gives the most reliable estimation that is free of any
reconstruction steps in either model-dependent or model-independent manner. Due to highly variable nature of the HVR1,
patient-specific consensus sequences were used in Bowtie 2
mapping under the relaxed mapping stringency at f(x) = 10+
8ln(x) for functional score setting [10]. Indexed BAM file from the
PLOS ONE | www.plosone.org
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Figure 6. The mutation frequency-based histogram of a total of
36,665 mutations identified in 56 patients (A), which fitted in
with a power law distribution (B) with the low-bound point
(xmin) at 296, corresponding with a mutation frequency at
17.5% (A). CDF, cumulative distribution function.
doi:10.1371/journal.pone.0100131.g006

Statistical analysis
Except for those statistical analyses stated specially, other
comparisons between SVR and null responders were done with
either two-tailed, unpaired Student’s t test or Fisher’s exact test.
Multivariate Analysis of Variance (MANOVA) among host and
viral factors possibly affecting the treatment outcome or the HCV
mutation load was executed with IBM SPSS software (version 20).
Data were expressed as mean value and standard derivation (SD)
and p,0.05 was considered statistically significant.

Data availability
Raw sequence data in fastq format from all 61 patient samples
were archived in NCBI Sequence Read Archive (SRA) under SRA
accession number SRP035878.

Results

Figure 7. Comparative HCV genome-wide sliding window
analyses (window size = 300 bp; overlap = 99 bp) between
SVR (blue) and null response group (red) according to
mutation nature, including total mutations (A), synonymous
mutations (B) and nonsynonymous mutations (C). Mutations
within each category were analyzed separately based on xmin translated
value (17.5%), i.e., low or high mutation frequencies. For each window,

Genome-wide quantification of HCV mutation load
The quantification of HCV mutation load was achieved by the
integration of the long RT-PCR technique [8], 454 sequencing
and bioinformatic pipelines. All viral mutations with the minimum
of 1% frequency in population were counted over the 9022-bp
PLOS ONE | www.plosone.org
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Low mutation load is associated with sustained
virological response (SVR)

average mutation frequency per site (left column) and normalized
entropy (right column) were compared for statistical significance as
represented by bars.
doi:10.1371/journal.pone.0100131.g007

The method established was used to examine potential
association between mutation load and the outcome of HCV
antiviral therapy. A total of 60 patients who underwent 48-week
peginterferon a-2a and ribavirin combination therapy were
selected from the HALT-C trial. After the exclusion of samples
that failed long RT-PCR amplification (n = 3) or the quality
control of 454 library preparation (n = 1), 454 sequencing of the
remaining 56 patient samples generated 1,454,077 reads with an
average read length at 444 bp, thereby an average theoretical
sequencing depth calculated at 1257x. After read quality control,
average 95.4% and 99.7% mapping rates were achieved with the
consensus sequences from HCV 1a clades and individual strains,
respectively. Actual per base coverage after read quality control
was 10946577x (Figure 4). There was no difference between SVR
(n = 26) and null responders (n = 30) with regard to the sequencing
depth and the read length (data not shown). For all 56 patients, we
identified 36,818 mutations and 1,616 indels at the resolution of
1% frequency in population. One patient had a large in-frame
1455-bp deletion in HCV structural region spanning E1 through
p7 (Figure S1), which was subsequently confirmed by the lack of
RT-PCR amplification using primers located in this domain (data
not shown). The mutation load, either the number of mutations or
the normalized entropy, varied widely among patients, ranging
from 92 to 1639 and 1.19 to 24.9, respectively. Notably, the
mutation load was significantly lower in the SVR compared to the
null responders, 5246279 vs. 8056271, p = 3.4761024 (mutation)
and 8.865.6 vs. 1465, p = 6.161024 (entropy) (Figure 5A).
Among 35 patients with unfavorable IL28B genotypes (CT and
TT), average mutation load per patient remained different
significantly between SVR and null responders (762.36228.6 vs.
618.36171.4, p = 0.01).
In contrast with an exponential distribution of HCV genetic
diversity measured by cloning and Sanger sequencing [6], the
histogram of mutation load presented a Poisson distribution

amplicon, spanning nearly 96% of the HCV genome from HCV
59UTR to NS5B region. To determine an appropriate sequencing
depth for comparable quantification of mutation load among
patients, we applied the method for five HCV patient samples with
known intra-population HCV HVR1 diversity [6]. The long RTPCR amplicons from these patients had an output of 567,904
reads with an average read length at 393.3 bp, which was
translated into an average sequencing depth at 4946x. Through
multiple random data extraction, we quantified mutation load at
various sequencing depths. For each sample, the mutation load
became stable with an average of 98% saturation upon
approaching the depth of 1100x (Figure 1A). As five samples
were selected in terms of their representative genetic diversity on
an exponential curve (low, moderate and high) [6], proportional
association between the genome-wide mutation load and the
genetic diversity was weak (R2 = 0.18, p = 0.26) (Figure 1B). A
theoretical calculation of per base sequencing depth $1100x was
applied in subsequent retrospective studies.
All structural variants over a 300-bp HCV domain, spanning
the HCV HVR1, were recovered from each of five patients at
theoretical sequencing depth of 1100x. The HVR1 variants
detected from either 454 sequencing or cloning/Sanger sequencing showed high phylogenetic consistency at the lineage level
(Figure 2). No additional HVR1 structural variants were found at
the depth of 2500x in all samples and even up to 4600x for
samples #1701 and #1709, which had the deepest base coverage.
Notably, the simulation experiment with these two samples
showed highly stable ratios among the read numbers supporting
each HVR1 structural variant over a range of depths (Figure 3).

Table 1. Comparisons of viral and host factors in the context of therapeutic outcomes (SVR vs. null) or mutation load (low vs.
high).

Treatment outcome

Factors

Mutation load

SVR vs. Null
Host Race

p value*

All Caucasian

Low vs. High

p value*

All Caucasian

Sex

All male

Age

48.464.71 vs. 4864.3

0.745

48.564.27 vs. 47.263.97

0.262

Weight (kg)

86.4613.1 vs. 90.3614.1

0.267

91.6615.24 vs. 86.3612.2

0.152

BMI

27.963.59 vs. 28.963.96

0.291

29.164.47 vs. 27.963.21

0.256

Ishak score

3.160.6 vs. 360.7

0.6

3.0460.64 vs. 3.1460.71

0.553

IL28B CC type

15/27 vs. 1/27

561025#

10/25 vs. 5/25

0.217#

HCV HCV genotype

All male

All genotype 1a

All genotype 1a

HCV RNA load (log10)

6.360.41 vs. 6.2460.49

0.423

6.1460.46 vs. 6.3660.38

0.051**

HVR1 variants

4.9662.23 vs. 5.0762.25

0.86

5.0462.4 vs. 4.9661.88

0.89

Genome scan

Full-length

Negative

Negative

Domains

Negative

NS5a and NS5b

*two-tailed Student’s t test;
#
Fisher’s exact test. BMI, body mass index;
**p = 0.063 after controlling other factors in MANOVA (F statistic = 3.62); Scanning indicates an approach to investigate the relatedness between genotypes and
phenotypes through calculating statistical significance of phylogenetic clustering.
doi:10.1371/journal.pone.0100131.t001

PLOS ONE | www.plosone.org
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Figure 8. Neighbor-Joining tree of 56 nearly full-length HCV consensus sequences (each 8817 bp in length spanning from HCV
Core to NS5b) under maximum composition likelihood model and gamma distribution of rate variation among sites (c = 0.5). HCV
genotype 1a prototype H77 strain was also included (blue branch). All strains were clustered apparently into two clades with 98% bootstrap
support.
doi:10.1371/journal.pone.0100131.g008

was compromised in most viral domains in the patterns with either
nonsynonymous or high-frequency ($17.5%) mutations (Figure 7).

(KS = 0.078, p = 0.25), which provided an intuitive view for the
correlation between HCV mutation load and treatment responses
(Figure 5B). Finally, no overall difference was observed with regard
to total numbers of the indels between SVR (27.469.6) and null
groups (30.1614.8) (p = 0.44). However, sliding window analysis
showed that three domains, one at NS4a and the others at the 59
end of NS5B, had significantly higher numbers of indels in SVR
than that in null responders (Figure S2).

Contribution of viral and host factors to the mutation
load
By a Poisson distribution pattern of the mutation load among 56
patients, the high or low mutation load was assigned using the

Viral population structures stratified by mutation
frequency and mutation nature
Of 36,818 mutations detected, most had low frequencies. The
histogram fitted either a lognormal (KS = 0.08, p = 0.78) or a
power law distribution (KS = 0.09, p = 0.84) (Figure 6). A slightly
higher p value, as defined in Clauset’s approach [19], suggested the
better acceptance of power law distribution for our data. The lowbound point (xmin) was calculated at 296, corresponding with a
mutation frequency at 17.5% (Figure 6A). Stratified by either
mutation frequency based on xmin (high vs. low) or mutation
nature (synonymous vs. nonsynonymous), the patterns of mutation
distribution gave a deep insight into viral population structure in a
genome-wide manner. Over the HCV coding region from Core to
NS5b that accounted for 36,665 mutations (99.6% of total
mutations), both mutation frequency and entropy had essentially
the same patterns in all stratifications (Figure 7). The magnitude of
differences was not apparent between SVR and null responders in
nonsynonymous but not in synonymous mutations (Figure 7). The
former had apparent mutation peaks, one in the E2 and the other
in the NS5a (Figure 7B), which were all lost in the patterns of
synonymous mutations (Figure 7C). Finally, statistical significance

PLOS ONE | www.plosone.org

Figure 9. Lack of correlation between individual HCV RNA
titers and mutation loads, including synonymous (R2 = 0.0015,
p = 0.77), nonsynonymous (R2 = 0.001, p = 0.82) and the combination (R2 = 0.0016, p = 0.76).
doi:10.1371/journal.pone.0100131.g009
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Figure 10. Linear regression analysis of the relatedness between high/low frequency mutation loads and respective total mutation
loads, i.e., synonymous and nonsynonymous mutations (A), nonsynonymous mutations (B) and synonymous mutations (C).
doi:10.1371/journal.pone.0100131.g010

approaches require an amplicon below the length of sequencing
reads and are thus not feasible for long RT-PCR. Under the
current experimental settings, we have estimated potential biases
that may vary largely among different protocols [29]. First, direct
454 sequencing of DNA templates has a mean error rate at 1.07%,
which requires $5x read coverage to correct an error [30]. The
mean sequencing depth in the current study is 10946577x after
data quality control, equivalent to a read coverage at 5.17x to
16.7x per mutation under 1% resolution of mutation frequency.
Thus most errors associated with 454 sequencing should be
corrected. Second, the long RT-PCR uses primers located in the
conserved regions of HCV genome to allow the full recovery of
viral variants [31]. The inclusion of Deep Vent DNA polymerase
in the enzyme blend (rTth, XL DNA polymerase) not only
facilitates the amplification of nearly full-length HCV genome but
also reduces artificial mutations owing to its strong 39R 59
proofreading exonuclease activity. In our previous study, erroneous substitution rate is approximately at 0.13% after 60-cycle PCR
cycles without the RT, translating into about 11.7 sites over 9022bp amplicon [32]. Thus potential PCR-associated errors should
have a minimal role on HCV mutation load measured in a
genome-wide manner. Such a minimal role is further debilitated
through a comparative analytical strategy in the present study.
Third, individual patient HCV mutation loads didn’t correlate
with viral titers (Figure 9), suggesting a minimal effect of the
template amount on the mutation load. Finally, in the simulation
experiment, the number of HVR1 structural variants and more
importantly, the relative ratio of sequencing reads supporting each
HVR1 structural variant, were fairly stable over various sequencing depths (Figure 3), indicating the lack of amplification bias at
least at the level of structural variants. Indeed, in spite of the
circulation as a heterogeneous population, the number of HCV
HVR1 structural variants was limited, ranging 1 to 9 variants, and
further reduced in terms of phylogenetic lineages (Figure S3).
Taken together, while we are unable to map potential bias relevant
to individual variants, above observation show that such a bias is
unlike to have a role in the genome-wide mutation load that
doesn’t have a focus on particular sites and mutations.
Applying this method to well-characterized human subjects, we
found the first unambiguous evidence that low mutation load in a
genome-wide manner is associated with the better response to
antiviral therapy. This conclusion remains effective when including only patients with unfavorable IL28B genotypes (CT and TT),
one of the strongest single factors to predict treatment outcomes
[33]. Thus, the HCV genome-wide mutation load at high
resolution appears to be an independent factor to predict the
therapeutic results. While excess mutations are detrimental to viral
population fitness [34,35], our data indicates a dominant role of

mean value (n = 654) of the total mutation number. Owing to a
well-matched selection of patients (Table S1), two groups with
either low or high mutation load had no difference on
demographic factors (race, sex, age and BMI) and disease status
(Ishak scores). Comparative analysis was thus focused on viral and
host genetic factors, including viral compartmentalization, viral
population size, viral strain difference and IL28B genotype. A total
of 319 HVR1 structural variants were recovered from 56 patients
(Figure S3). The average number of structural HVR1 variants per
patient was not different between two groups, 4.9662.24 vs.
5.0762.25, p = 0.86 (Table 1). Similarly, the mutation load was
not apparently associated with HCV RNA titers (6.1460.46 vs.
6.3660.38, p = 0.051) (Table 1). Of fifty patients with the
availability of both mutation load and IL28B genotype data,
patients with IL28B CC type had significant low mutation load in
comparison with non-CC types (CT and TT), 4806341 vs.
7216221, p = 0.004, corresponding with the count of double
number of patients with IL28B CC type in the group of low
mutation load in spite of the lack of statistical significance (Table 1).
Finally, except for the body weight and BMI, MANOVA analysis
did not find any significant covariance among host and viral
factors in terms of the treatment outcome or the mutation load (all
p values.0.2).
Next, we determined if any particular HCV 1a strain or viral
domains were associated with the mutation load through a
phylogenetic approach. On the full-length HCV phylogenetic tree,
the strains derived from 56 patients were clustered into two clades,
clade 1 (n = 40) and clade 2 (n = 16) (Figure 8). The analysis was
thus performed for the clades 1 and 2, respectively. At the fulllength HCV genome level, no association between phylogenetic
clustering and mutation loads was found in either clade 1 or clade
2 (AI and PS, p.0.01, Table S2). However, in a genome-wide
domain scan, two domains, domains 34 and 39 respectively
located in NS5a and NS5b, showed significant mutation loaddependent clustering in both HCV clades (AI and PS, p,0.01,
Table S2). Similar analysis showed no relationship in the context
of the treatment outcome (Table S2).

Discussion
In this study, genome-wide quantification of HCV mutation
load at a high resolution was achieved through the integration of
long RT-PCR, 454 sequencing and bioinformatic tools. RT-PCR
of heterogeneous templates is known to be associated with
introduction of artificial mutations as well as amplification bias.
Recently, several studies reported the use of sequence identifiers in
primers for RT or PCR, which allow subsequent monitoring of
amplification bias in 454 sequencing data [27,28]. However, these
PLOS ONE | www.plosone.org

8

June 2014 | Volume 9 | Issue 6 | e100131

HCV Genome-Wide Mutation Load and Antiviral Therapy

natural selection even in patients with high mutation loads, which
maximize the potential of HCV mutational pathways to counteract antiviral drugs, as observed in recent in vitro experiment [36].
In-depth analysis of the mutation load explains previous
conflicting data with regard to the predicting value of viral
population structure in HCV antiviral therapy. The power-law
pattern of mutation histogram had a low-bound point crossed with
a mutation frequency at 17.5% (Figure 6), which is beyond the
detection limit of common methods like gel shift analysis or
cloning and Sanger sequencing [37,38]. However, it should be
noted that conventional cloning and Sanger sequencing is
comparable with 454 sequencing for the recovery of structural
HCV HVR1 variants at the level of phylogenetic lineages
(Figure 2). The low-frequency mutation load, but not the highfrequency, is proportional strongly to total mutation loads of
synonymous (R2 = 0.923, p,0.0001), nonsynonymous (R2 = 0.807,
p,0.0001) or the combination (R2 = 0.906, p,0.0001) (Figure 10).
Consequently, the genome-wide sliding window analysis revealed
that statistical significance in most regions were compromised
upon exclusive inclusion of high-frequency mutations (.17.5%)
(Figure 9). Interestingly, the HCV HVR1, a domain used
frequently in viral diversity studies, is less powerful in distinguishing SVR from null responders (Figure 7). Thus conflicting data
obtained with common methods appears to be the result of lowresolution of mutation detection.
Our analysis further reveals that multiple forces together shape
the viral population structure. Although not absolute, synonymous
and nonsynonymous mutations are commonly interpreted as the
reflection of selective and neutral forces, respectively [39].
Confirming to this assertion, sliding window analysis of nonsynonymous, but not synonymous mutations, shows an apparent peak in
the HVR1, a well-documented region under high immune
selection [40]. The higher number of nonsynonymous mutations
thus suggests a stronger immune pressure in the SVR group
compared to the null responders (Figure 5). Second, among 36,665
mutations detected in HCV coding region from 56 patients,
24,375 (66.48%) are low-frequency synonymous mutations from
which statistical significance stems mostly (Figure 7). Given
comparable numbers of structural HCV HVR1 variants between
SVR and null responders (Table 1), viral compartmentation, often
associated with distinct HCV HVR1 variants [41], might play a
negligible role in the contribution to observational difference of the
mutation load. Therefore genetic drift and its magnitude might be
a reasonable explanation for both mutation accumulation and
differential mutation loads in SVR and null responders. Third, two
HCV domains, respectively located in NS5a and NS5b, showed
significant mutation load-dependent clustering (Table S2). The
NS5b encodes RNA-dependent RNA polymerase that drives an
error-prone viral replication. Mutations in NS5b or nearby
regions, together with increasing number of indels (Figure S2),
may have a direct effect on strains’ intrinsic mutation rates. Lastly,
it was interesting to note that the low mutation load was associated
with IL28B CC type, one of single strongest predictors in
interferon-based HCV antiviral therapy. Taken together, these
data may delineate a scenario regarding the generation and
modulation of HCV mutation load. Besides direct contribution of
nonsynonymous mutations, the HCV-target immunity, both
innate and adaptive, modulate viral replication dynamics that
affect the strength of genetic drift by coupling with viral intrinsic
mutation rates. While molecular mechanisms underpinning these
observations remain largely unknown, it is clear that no single
factors from either virus or host side could dominate the mutation

PLOS ONE | www.plosone.org

load in chronic HCV infection. A power law distribution among
patients indeed signifies the operation of potential multiple-level
hierarchies on the modulation of HCV mutation load.
In conclusion, by establishing a method for genome-wide
quantitation of HCV mutation load, the current study explains
previous conflicting observation and intensifies a dominant role of
natural selection in HCV population in response to interferonbased antiviral therapy. We showed that intra-patient HCV
population structure attains the signatures from complex interaction between host and virus. Thereby the high-resolution
quantitation of HCV mutation load could be a useful approach
to evaluate outcomes in interferon-based antiviral therapy and
potentially in other clinical settings.

Supporting Information
Figure S1 A graphic illustration of read alignment in
patient Q52 against the consensus sequence of HCV
genotype 1a clade 1, which showed a 1455-bp large
structural deletion from position 1203 to 2657 according
to HCV genotype 1a prototype H77 (Genbank accession
number AF009606).
(TIF)
Figure S2 Sliding window analysis of indels. Of 1,616
indels identified in 56 patient samples, the sliding window analysis
(window size = 300 bp, overlap = 100 bp) showed similar distribution patterns over HCV genome and in most domains, i.e., 42 of
45 windows, statistical significance, represented by bars, was not
approached by two-way student’s t test between SVR (blue) and
null responders (red). Three domains located in NS4a and NS5b
had significantly higher numbers of indels in SVR than that in null
responders.
(TIF)
Figure S3 Neighbor-Joining tree of 319 structural
variants (each 300 bp) spanning HCV HVR1 domain,
which were recovered from read libraries of 56 patients
except for patient Q52 who had a large in-frame
structural deletion. Bootstrap test was done with 500 replicates
and the support (percentage) was shown at major branches.
(TIF)
Table S1 An overview of demographic, virological,
disease status and genetic information of 60 patients
enrolled in the study.
(DOCX)
Table S2 Results of BaTS analysis based on either
nearly full-length HCV 1a genome (8817 bp) or genome
scan.
(DOCX)
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